Articles | Open Access | https://doi.org/10.37547/ijmscr/Volume05Issue08-05

Osteoporosis in Women with Rheumatic Diseases

Rakhmatova Feruza Uraimovna , Assistant, Department of Hospital Therapy (Laboratory), Fergana Medical Institute of Public Health, Uzbekistan

Abstract

Objective. To summarize current data (through August 2025) on the epidemiology, risk factors, diagnosis, and treatment of osteoporosis in women with rheumatic diseases (RD), including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), axial spondyloarthritis/ankylosing spondylitis (axSpA/AS), and psoriatic arthritis (PsA).

Methods. A targeted review was conducted with a description of the search methodology (PubMed/MEDLINE, PubMed Central, Web of Science), as well as an analysis of current clinical guidelines (ACR/EULAR, ISCD, IOF/BHOF). Systematic reviews/meta-analyses, large cohort studies, and randomized clinical trials on the diagnosis and treatment of postmenopausal osteoporosis and glucocorticoid-induced osteoporosis (GIOP) published in 2015–2025 were included, with priority given to 2023–2025.

Results. In women with RA, the prevalence of osteoporosis reaches ~28% (95% CI 24–31%) according to meta-analysis data, which is higher than in the general population of similar age; in patients with SLE, the risk of osteoporotic fractures in population-based cohort studies is almost three times higher than in matched controls. For axSpA/AS, an increased burden of low bone mineral density (BMD) and predominantly vertebral fractures has been shown; in PsA, fracture risk also increases (including vertebral fractures). Modifiable risk factors include inflammation, immobilization, calcium/vitamin D insufficiency, smoking, and especially the use of systemic glucocorticoids (dose-dependent effect). The diagnostic gold standard is dual-energy X-ray absorptiometry (DXA) according to the ISCD 2023 positions; for risk stratification, FRAX/FRAXplus and adjustment with trabecular bone score (TBS) are recommended. Assessment of vertebral fractures (VFA/radiography) is mandatory in RD and glucocorticoid therapy. Bone turnover markers (P1NP, β-CTX) are useful for monitoring treatment response.

Prevention and treatment include lifestyle modification; adequate calcium and vitamin D intake; and pharmacotherapy according to risk level. Bisphosphonates, denosumab, teriparatide/abaloparatide, and romosozumab have proven anti-fracture efficacy; for GIOP, the ACR 2023 recommendations are relevant, prioritizing anabolic therapy in very high-risk individuals and mandatory sequential antiresorptive therapy after discontinuation of denosumab/anabolics. Selective estrogen receptor modulators and menopausal hormone therapy are considered in specific clinical scenarios.

Conclusions. In women with RD, osteoporosis occurs more often and manifests earlier due to the combination of chronic inflammation, estrogen deficiency (menopause), and the effects of glucocorticoids. Early risk identification (DXA + FRAX/FRAXplus + TBS), timely initiation of therapy, and multidisciplinary management (rheumatologist–endocrinologist–physician–rehabilitation specialist) reduce the fracture burden. Practical proposals for screening and treatment are presented, as well as unresolved issues and directions for future research.

Keywords

Osteoporosis, rheumatoid arthritis, systemic lupus erythematosus

References

Humphrey MB, Russell L, Danila MI, et al. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol. 2023;75(12):2088–2102. doi:10.1002/art.42646.

International Society for Clinical Densitometry (ISCD). Official Positions (Adult), 2023. 2023. Available at: https://iscd.org/learn/official-positions/ (accessed August 26, 2025).

University of Sheffield. FRAX adjusted for TBS. Available at: https://frax.shef.ac.uk/tbs/ (accessed August 26, 2025).

University of Sheffield. FRAXplus® (Beta). Available at: https://fraxplus.org/frax-plus (accessed August 26, 2025).

Moshayedi S, Tasorian B, Almasi-Hashiani A. The prevalence of osteoporosis in rheumatoid arthritis patient: a systematic review and meta-analysis. Sci Rep. 2022;12:15844. doi:10.1038/s41598-022-20016-x.

Gu C, Zhao R, Zhang X, et al. A meta-analysis of secondary osteoporosis in systemic lupus erythematosus: prevalence and risk factors. Arch Osteoporos. 2019;15(1):1. doi:10.1007/s11657-019-0667-1. PMID:31802295.

Kyoto Lupus Cohort. Factors associated with osteoporosis and fractures in patients with systemic lupus erythematosus. Mod Rheumatol. 2023; (epub ahead of print; PMID:36680424).

Li X, et al. Bone Mineral Density and Fracture Risk in Ankylosing Spondylitis: A Meta-Analysis. Calcif Tissue Int. 2017;101:182–192.

Voskanyan A, et al. The prevalence of vertebral fractures in ankylosing spondylitis and DISH: a systematic review and meta-analysis. NASSJ (North Am Spine Soc J). 2024; (PubMed/PMC available).

Chen TL, Lu JW, Huang YW, et al. Bone Mineral Density, Osteoporosis, and Fracture Risk in Adult Patients with Psoriasis or Psoriatic Arthritis: A Systematic Review and Meta-Analysis. J Clin Med. 2020;9(11):3712. doi:10.3390/jcm9113712.

Stevenson JC, on behalf of British Menopause Society. Prevention and treatment of osteoporosis in women. Post Reprod Health. 2023;29(1):3–28. doi:10.1177/20533691221139902.

Liu Y, et al. Association between biologic therapy and fracture incidence in rheumatic and autoimmune diseases: a systematic review and meta-analysis of RCTs. Osteoporos Int. 2022;33: (ahead of print). PMID:35644324.

Rejnmark L, et al. Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: network meta-analysis. BMJ. 2023;381:e068033. doi:10.1136/bmj-2021-068033.

Saag KG, Pannacciulli N, Geusens P, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol. 2018;6(6):445–454.

Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension. Lancet Diabetes Endocrinol. 2017;5(7):513–523.

Saag KG, Shane E, Boonen S, et al. Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis. N Engl J Med. 2007;357:2028–2039.

Miller PD, Hattersley G, Riis BJ, et al. Abaloparatide versus Placebo in Postmenopausal Women with Osteoporosis (ACTIVE). N Engl J Med. 2016;375:721–731.

Saag KG, Petersen J, Brandi ML, et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med. 2017;377:1417–1427.

Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: 3-year randomized clinical trial (MORE). JAMA. 1999;282(7):637–645.

Siris ES, Adachi JD, Lu Y, et al. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from MORE. Osteoporos Int. 2002;13(11):907–913.

Menopause Journal. Association of hormone preparations with bone mineral density in postmenopausal women. Menopause. 2023;30(6): (online). DOI available on the journal website.

International Osteoporosis Foundation. Using FRAXplus to address limitations of FRAX (news overview). 2023. Available at: https://www.osteoporosis.foundation/news/new-fraxplusr-beta-version-illustrates-potential-refined-risk-factor-information-entered.

Article Statistics

Copyright License

Download Citations

How to Cite

Rakhmatova Feruza Uraimovna. (2025). Osteoporosis in Women with Rheumatic Diseases. International Journal of Medical Sciences And Clinical Research, 5(08), 22–26. https://doi.org/10.37547/ijmscr/Volume05Issue08-05